| Orginal Article |
|
|
|
|
| Comprehensive Evaluation is needed for Precision Diagnosis in Cancer Immunotherapies |
Lin YANG,Yong-chao LI,Teng-hua ZHANG,Yi-xiao DENG,Jin YANG,Zhi-bo GAO( ) |
| Yuce Biotechnology Co.,Ltd,Shenzhen 518081,China |
|
|
|
Abstract Cancer immunotherapies has become one of the important approaches in advanced malignant tumor treatments. The immunotherapies attack tumors by reinvigorating the human immune system, which will change the paradigm of cancer treatment. The immunotherapies, including anti-PD-1/L1 and anti-CTLA-4 antibodies, have improved the five-year survival rate of patients with malignant tumors, and have been recognized as the most promising treatments to cure cancer. However, only a subset of patients benefits from the immunotherapy, and there are problems such as drug resistance, hyperprogression disease, and immune-related adverse events. Thus, the early selection of the most sensitive patients is key, and the development of predictive biomarkers is one of the biggest challenges of cancer immunotherapy development. Many biomarkers are under investigation, and they are potentially applicable to the clinical selection of patients for immunotherapies, but each has limited utility. Comprehensive evaluation of multiple indicators around the sensitivity and the adverse events of immunotherapies will be the direction of the future. In this article, we will review the research progress in cancer immunotherapies and comprehensive evaluation of precision cancer diagnosis.
|
|
Received: 10 January 2019
Published: 26 March 2019
|
|
|
|
|
| [1] |
高志博, 杨锦 . 肿瘤精准免疫治疗与基因检测. 生物产业技术, 2017,58(02):27-33.
doi: 10.3969/j.issn.1674-0319.2017.02.004
|
|
|
| [1] |
Gao Z B, Yang J . Genetic testing for precision cancer immunotherapy. Biotechnology & Business, 2017,58(02):27-33.
doi: 10.3969/j.issn.1674-0319.2017.02.004
|
|
|
| [2] |
Sharma P, Hu-Lieskovan S, Wargo J A , et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 2017,168(4):707-723.
doi: 10.1016/j.cell.2017.01.017
pmid: 28187290
|
|
|
| [3] |
Topalian S L, Hodi F S, Brahmer J R , et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine, 2012,366(26):2443-2454.
doi: 10.1056/NEJMoa1200690
|
|
|
| [4] |
Robert C, Long G V, Brady B , et al. Nivolumab in previously untreated melanoma without braf mutation. New England Journal of Medicine, 2015,372(4):320-330.
doi: 10.1056/NEJMoa1412082
|
|
|
| [5] |
Robert C, Schachter J, Long G V , et al. Pembrolizumab versus Ipilimumab in advanced melanoma. New England Journal of Medicine, 2015,372(26):2521-2532.
doi: 10.1056/NEJMoa1503093
pmid: 25891173
|
|
|
| [6] |
Gettinger S N, Horn L, Gandhi L , et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. Journal of Clinical Oncology, 2015,33(18):2004-2012.
doi: 10.1200/JCO.2014.58.3708
|
|
|
| [7] |
Rizvi N A, Mazières Julien, Planchard D , et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. The Lancet Oncology, 2015,16(3):257-265.
doi: 10.1016/S1470-2045(15)70054-9
|
|
|
| [8] |
Garon E B, Rizvi N A, Hui R , et al. Pembrolizumab for the treatment of non-small-cell lung cancer. New England Journal of Medicine, 2015,372(21):2018-2028.
doi: 10.1056/NEJMoa1501824
pmid: 25891174
|
|
|
| [9] |
Borghaei H, Paz-Ares L, Horn L , et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. New England Journal of Medicine, 2015,373(17):1627-1639.
doi: 10.1056/NEJMoa1507643
pmid: 4681400
|
|
|
| [10] |
Brahmer J, Reckamp K L, Baas P , et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New England Journal of Medicine, 2015,373(2):123-135.
doi: 10.1056/NEJMoa1507643
pmid: 4681400
|
|
|
| [11] |
Daud A I, Wolchok J D, Robert C , et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. Journal of Clinical Oncology, 2016,34(34):4102-4109.
doi: 10.1200/JCO.2016.67.2477
pmid: 27863197
|
|
|
| [12] |
Reck M, Rodríguez-Abreu D, Robinson A G , et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New England Journal of Medicine, 2015,375(19):1823-1833.
doi: 10.1056/NEJMoa1606774
pmid: 27718847
|
|
|
| [13] |
Hansen A R, Siu L L . PD-L1 testing in cancer: challenges in companion diagnostic development. Jama Oncology, 2016,2(1):15-16.
doi: 10.1001/jamaoncol.2015.4685
|
|
|
| [14] |
Sacher A G, Gandhi L . Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer. JAMA Oncology, 2016,2(9):1217-1222.
doi: 10.1001/jamaoncol.2016.0639
pmid: 27310809
|
|
|
| [15] |
Mandal R, Chan T A . Personalized oncology meets immunology: the path toward precision immunotherapy. Cancer Discovery, 2016,6(7):703-713.
doi: 10.1158/2159-8290.CD-16-0146
pmid: 27107038
|
|
|
| [16] |
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature, 2014,511(7511):543-550.
doi: 10.1038/nature13385
|
|
|
| [17] |
Shukuya T, Carbone D P . Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. Journal of Thoracic Oncology, 2016,11(7):976-988.
doi: 10.1016/j.jtho.2016.02.015
pmid: 26944305
|
|
|
| [18] |
Schumacher T N, Schreiber R D . Neoantigens in cancer immunotherapy. Science, 2015,348(6230):69-74.
doi: 10.1126/science.aaa4971
|
|
|
| [19] |
Snyder A, Makarov V, Merghoub T , et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. New England Journal of Medicine, 2014,371(23):2189-2199.
doi: 10.1056/NEJMc1415938
pmid: 4315319
|
|
|
| [20] |
Van Allen E M, Miao D, Schilling B , et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 2015,350(6257):207-211.
doi: 10.1126/science.aad0095
|
|
|
| [21] |
Rizvi N A, Hellmann M D, Snyder A , et al. Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer. Science, 2015,348(6230):124-128.
doi: 10.1126/science.aaa1348
pmid: 25765070
|
|
|
| [22] |
Rosenberg J E, Hoffman-Censits J, Powles T , et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, 2016,387(10031):1909-1920.
doi: 10.1016/S0140-6736(16)00561-4
pmid: 26952546
|
|
|
| [23] |
McGranahan N, Furness A J, Rosenthal R , et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016,351(6280):1463-1469.
doi: 10.1126/science.aaf1490
|
|
|
| [24] |
Le D T, Uram J N, Wang H , et al. PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 2015,372(26):2509-2520.
doi: 10.1056/NEJMoa1500596
|
|
|
| [25] |
Brahmer J R, Drake C G, Wollner I , et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology, 2010,28(19):3167-3175.
doi: 10.1200/JCO.2009.26.7609
|
|
|
| [26] |
Remon J, Chaput N, Planchard D . Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. Current Opinion in Oncology, 2016,28(2):122-129.
doi: 10.1097/CCO.0000000000000263
pmid: 26756384
|
|
|
| [27] |
Tumeh P C, Harview C L, Yearley J H , et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 2014,515(7528):568-571.
doi: 10.1038/nature13954
pmid: 25428505
|
|
|
| [28] |
Herbst R S, Soria J C, Kowanetz M , et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014,515(7528):563-567.
doi: 10.1038/nature14011
|
|
|
| [29] |
Daud A I, Loo K, Pauli M L , et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. Journal of Clinical Investigation, 2016,126(9):3447-3452.
doi: 10.1172/JCI87324
pmid: 5004965
|
|
|
| [30] |
Nghiem P, Bhatia S, Daud A , et al. 22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma. European Journal of Cancer, 2015,51:S720-S721.
|
|
|
| [31] |
Elkhoueiry A B, Melero I, Crocenzi T S , et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma ( HCC): CA209-040. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2015, 33(18_suppl): LBA101.
doi: 10.1200/jco.2015.33.18_suppl.lba101
pmid: 28147715
|
|
|
| [32] |
Martens A, Wistubahamprecht K, Eigentler T K , et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clinical Cancer Research, 2016,22(12):2908-2918.
doi: 10.15496/publikation-14544
pmid: 26787752
|
|
|
| [33] |
Delyon J, Mateus C, Lefeuvre D , et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Annals of Oncology, 2013,24(6):1697-1703.
doi: 10.1093/annonc/mdt027
pmid: 23439861
|
|
|
| [34] |
Kelderman S , Heemskerk B, van Tinteren H, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunology, Immunotherapy, 2014,63(5):449-458.
|
|
|
| [35] |
Gebhardt C, Sevko A, Jiang H , et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clinical Cancer Research, 2015,21(24):5453-5459.
doi: 10.1158/1078-0432.CCR-15-0676
|
|
|
| [36] |
Tietze J K, Angelova D, Heppt M V , et al. The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. European Journal of Cancer, 2017,75:268-279.
doi: 10.1016/j.ejca.2016.12.031
pmid: 28242504
|
|
|
| [37] |
Diem S, Kasenda B, Spain L , et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. British Journal of Cancer, 2016,114(3):256-261.
doi: 10.1038/bjc.2015.467
pmid: 47425881
|
|
|
| [38] |
Weide B, Martens A, Hassel J C , et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clinical Cancer Research, 2016,22(22):5487-5496.
doi: 10.1158/1078-0432.CCR-16-0127
pmid: 27185375
|
|
|
| [39] |
Ayers M, Lunceford J, Nebozhyn M , et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. The Journal of Clinical Investigation, 2017,127(8):2930-2940.
doi: 10.1172/JCI91190
|
|
|
| [40] |
Cristescu R, Mogg R, Ayers M , et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science, 2018, 362(6411): eaar3593.
|
|
|
| [41] |
Ott P A, Bang Y J , Piha-Paul S A, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. Journal of clinical oncology. 2019,37(4):318-327.
|
|
|
| [42] |
Chowell D , Morris L G T, Grigg C M, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 2018,359(6375):582-587.
doi: 10.1126/science.aao4572
pmid: 29217585
|
|
|
| [43] |
McGranahan N, Rosenthal R, Hiley C T , et al. Allele-specific hla loss and immune escape in lung cancer evolution. Cell, 2017,171(6):1259-1271.
doi: 10.1016/j.cell.2017.10.001
pmid: 29107330
|
|
|
| [44] |
Marie Vétizou, Pitt J M, Romain Daillère , et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 2015,350(6264):1079-1084.
doi: 10.1126/science.aad1329
pmid: 26541610
|
|
|
| [45] |
Sivan A, Corrales L, Hubert N , et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science, 2015,350(6264):1084-1089.
doi: 10.1126/science.aac4255
|
|
|
| [46] |
Dubin K, Callahan M K, Ren B , et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nature Communications, 2016,7:10391.
doi: 10.1038/ncomms10391
pmid: 26837003
|
|
|
| [47] |
Champiat S, Dercle L, Ammari S , et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clinical Cancer Research, 2017,23(8):1920-1928.
doi: 10.1158/1078-0432.CCR-16-1741
pmid: 27827313
|
|
|
| [48] |
Kato S, Goodman A M, Walavalkar V , et al. Hyper-progressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clinical Cancer Research, 2017,23(15):4242-4250.
doi: 10.1158/1078-0432.CCR-16-3133
pmid: 28351930
|
|
|
| [49] |
Larkin J, Chiarion-Sileni V, Gonzalez R , et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 2015,373(1):23-34.
doi: 10.1056/NEJMoa1504030
pmid: 26027431
|
|
|
| [50] |
Wolchok J D, Kluger H, Callahan M K , et al. Nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine, 2013,369(2):122-133.
doi: 10.1056/NEJMoa1302369
pmid: 23724867
|
|
|
| [51] |
Hellmann M D, Callahan M K, Awad M M, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell, 2018, 33(5): 853-861. e4.
doi: 10.1016/j.ccell.2018.04.001
pmid: 29731394
|
|
|
| [52] |
Khagi Y, Goodman A M, Daniels G A , et al. Hypermutated circulating tumor dna: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res, 2017,23:5729-5736.
doi: 10.1158/1078-0432.CCR-17-1439
pmid: 28972084
|
|
|
| [53] |
Gandara D R, Paul S M, Kowanetz M , et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nature Medicine, 2018,24(9):1441-1448.
doi: 10.1038/s41591-018-0134-3
|
|
|
| [54] |
Chen G, Huang A C, Zhang W , et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature, 2018,560(7718):382-386.
doi: 10.1038/s41586-018-0392-8
|
|
|
| [55] |
Krieg C, Nowicka M, Guglietta S , et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nature Medicine, 2018,24(2):144-153.
doi: 10.1038/nm.4466
pmid: 29309059
|
|
|
| [56] |
Sanmamed M, Perez-Gracia J, Schalper K , et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients. Annals of Oncology, 2017,28(8):1988-1995.
doi: 10.1093/annonc/mdx190
pmid: 28595336
|
|
|
| [57] |
Siravegna G, Marsoni S, Siena S , et al. Integrating liquid biopsies into the management of cancer. Nature Reviews Clinical Oncology, 2017,14(9):531-548.
doi: 10.1038/nrclinonc.2017.14
|
|
|
| [58] |
Lee J H, Long G V, Menzies A M , et al. Association between circulating tumor dna and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncology, 2018,4(5):717-721.
doi: 10.1001/jamaoncol.2017.5332
|
|
|
| [59] |
Tang J, Yu J X , Hubbard-Lucey V M, et al. Trial watch: the clinical trial landscape for PD1/ PDL1 immune checkpoint inhibitors. Nature Reviews Drug Discovery, 2018,17(12):854-855.
doi: 10.1038/nrd.2018.210
|
|
|
| [60] |
Sanmamed M F, Chen L . A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell, 2018,175(2):313-326.
doi: 10.1016/j.cell.2018.09.035
|
|
|
| [61] |
Chen D S, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity, 2013,39(1):1-10.
doi: 10.1016/j.immuni.2013.07.012
|
|
|
| [62] |
Socinski M A, Jotte R M, Federico C , et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. New England Journal of Medicine, 2018,378(24):2288-2301.
doi: 10.1056/nejmoa1716948
pmid: 29863955
|
|
|
| [63] |
Blank C U, Haanen J B, Ribas A , et al. The “cancer immunogram”. Science, 2016,352(6286):658-660.
doi: 10.1126/science.aaf2834
|
|
|
| [64] |
Karasaki T, Nagayama K, Kuwano H , et al. An Immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer. Journal of Thoracic Oncology, 2017,12(5):791-803.
doi: 10.1016/j.jtho.2017.01.005
pmid: 28088513
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
